10-Q: Aethlon Medical Reports Q1 2026 Results, Focus on Oncology Trial

Aethlon Medical's Q1 2026 Form 10-Q filing details ongoing clinical development for its Hemopurifier, continued net losses, and a recent capital raise.

Summary

• Aethlon Medical, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $1,547,912 for the three months ended June 30, 2026, a decrease from $1,761,858 in the same period of 2025.
• Total operating expenses decreased by 11.9% to $1,579,202 from $1,792,390 year-over-year.
• As of June 30, 2026, the company had $4,933,579 in cash and cash equivalents.
• The company completed a registered public offering on July 7, 2026, raising approximately $4.0 million in gross proceeds.
• A 1-for-5 reverse stock split was effected on July 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to continued net losses, reliance on future capital raises, and the absence of revenue, despite progress in clinical trials and a recent capital infusion.

Positives

• Net loss decreased to $1,547,912 for Q1 2026 from $1,761,858 in Q1 2025.
• Total operating expenses decreased by 11.9% to $1,579,202 in Q1 2026 compared to Q1 2025.
• The company completed a public offering on July 7, 2026, raising approximately $4.0 million in gross proceeds.
• The Hemopurifier has received FDA Breakthrough Device designation for two indications.
• Preliminary observations from the Australian oncology trial show generally consistent directional changes across multiple biomarkers.
• A manuscript detailing extracellular vesicle characteristics in Long COVID patients was accepted for publication.

Negatives

• The company continues to incur significant net losses, with a loss of $1,547,912 for the three months ended June 30, 2026.
• The company has no revenue and relies on external financing to fund operations.
• Net cash used in operating activities was approximately $1.9 million for the three months ended June 30, 2026.
• The company will likely require additional capital in the future to continue advancing clinical development beyond the next twelve months.
• Stock-based compensation expense was $50,000 for the three months ended June 30, 2026, compared to $72,442 in the prior year period.

Risks

• The company's ability to continue as a going concern is dependent on its ability to secure additional financing.
• The Hemopurifier is an investigational device, and its efficacy and safety have not been fully established.
• The company faces competition from other providers and products in the oncology and infectious disease markets.
• Product development risks, including the inability to raise capital to fund continuing operations.
• Changes in government regulation could impact the company's development and commercialization efforts.
• Uncertainty of market acceptance for the Hemopurifier.
• Patent protection for the Hemopurifier technology may expire before FDA approval or approval in foreign countries.

Future Outlook

Management believes that current cash resources, along with proceeds from recent financing, will be sufficient to fund planned operations for at least twelve months. However, additional capital will likely be required beyond that period to continue advancing clinical development. Future capital requirements will depend on clinical and preclinical program progress, regulatory activities, manufacturing needs, and other operating expenditures. Additional financing may be sought through equity offerings, debt financings, or strategic collaborations.

Management Comments

• Preliminary observations from the Australian oncology trial demonstrated generally consistent directional changes across multiple biomarkers associated with tumor-derived extracellular vesicles, immune function and response to immunotherapy, supporting continued evaluation.
• The company's cash and cash equivalents, together with proceeds from financing completed in July 2026, will be sufficient to fund planned operations for at least twelve months from the date these condensed consolidated financial statements are issued.
• We will likely require additional capital in the future to continue advancing the clinical development of the Hemopurifier beyond that period.

Industry Context

StockSavvy.ai notes that Aethlon Medical operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel therapeutic devices. The company's progress is heavily reliant on successful clinical trial outcomes and its ability to secure ongoing funding, which is common for companies at this stage of development.

Comparison to Industry Standards

• Companies in the clinical-stage biotechnology sector often experience significant net losses and rely on frequent capital raises to fund research and development, similar to Aethlon Medical.
• The FDA's Breakthrough Device designation is a positive indicator, aligning with industry trends where regulatory support can accelerate development for promising technologies.
• The focus on extracellular vesicles (EVs) as therapeutic targets is an emerging area within the broader oncology and infectious disease research landscape.

Legal Proceedings

• The company is not currently a party to any material pending legal proceedings.

Related Party Transactions

• Accrued unpaid fees of $68,250 owed to non-employee directors for the three months ended June 30, 2026.

Stakeholder Impact

• Shareholders: Continued dilution risk due to reliance on equity financing and ongoing net losses. Potential upside if clinical trials are successful.
• Creditors: The company's ability to meet short-term obligations appears stable due to cash on hand and recent financing, but long-term viability depends on future funding.
• Employees: Continued employment is dependent on the company's ability to secure funding and achieve development milestones.
• Suppliers: Payment for services and goods is dependent on the company's cash flow and financing activities.

Next Steps

• Continue enrollment in the Australian oncology trial across three clinical sites.
• Complete the safety, feasibility, and dose-finding oncology trial in patients with solid tumors.
• Continue to explore potential new applications for the Hemopurifier through internal pre-clinical research and academic collaborations.
• Evaluate future facility requirements, including lease renewals or modifications.
• Seek additional financing as needed to fund operations beyond the next twelve months.

Key Dates

Recommendation

The company shows progress in its clinical trials and has secured additional funding, which are positive signs. However, the persistent net losses, lack of revenue, and the need for future capital raises present significant risks. A 'hold' recommendation reflects a balanced view of the potential upside from successful clinical development against the substantial financial and execution risks.

Keywords

Hemopurifier, Oncology, Extracellular Vesicles, Clinical Trial, FDA, Breakthrough Device, Viral Infections, Long COVID